Annovis Bio, Inc. Loss Contingency, New Claims Filed, Number
Annovis Bio, Inc. (ANVS) reported Loss Contingency, New Claims Filed, Number of 2 lawsuit for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Notes › Loss Contingency, Quantities
us-gaap:LossContingencyNewClaimsFiledNumber · last filed 2023-03-31
- Annovis Bio, Inc. loss contingency, new claims filed, number for the quarter ending 2021-09-30 was 2.00 lawsuit.
- Annovis Bio, Inc. loss contingency, new claims filed, number for fiscal 2021 was 2.00 lawsuit.
| Period end | Loss Contingency, New Claims Filed, Number 3 month | Loss Contingency, New Claims Filed, Number 12 month |
|---|---|---|
| 2021-12-31 | 2.00 lawsuit 10-K · filed 2023-03-31 | |
| 2021-09-30 | 2.00 lawsuit 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |